Veracyte Inc reports results for the quarter ended June 30 - Earnings Summary

Veracyte

31/07/2026 05:42

Veracyte Inc VCYT.OQ reported quarterly adjusted earnings of 31 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -1 cents.  The mean expectation of twelve analysts for the quarter was for earnings of 24 cents per share. Wall Street expected results to range from 19 cents to 27 cents per share.
Revenue rose 15.5% to $150.32 million from a year ago; analysts expected $144.55 million. 
Veracyte Inc's reported EPS for the quarter was 31 cents​.
The company reported quarterly net income of $25.49 million.
Veracyte Inc shares had fallen by 5.1% this quarter and gained 32.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.1% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Veracyte Inc is $56.00, about 6.8% above its last closing price of $59.78
This summary was machine generated from LSEG data July 31 at 04:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.24
0.31
Beat
Mar. 31 2026 
0.15
0.35
Beat
Dec. 31 2025 
0.22
0.51
Beat
Sep. 30 2025 
0.13
0.24
Beat